|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
| Racial Differences in Bladder Cancer Detection Using Blue Light Cystoscopy: A Multi-Center Study |
| Siamak Daneshmand, MD |
| Ashish Kamat welcomes Siamak Daneshmand to discuss the nuances of blue light cystoscopy and its effectiveness across different racial groups. Dr. Daneshmand discusses his team’s research into racial differences in tumor detection rates using blue light cystoscopy. |
|
|
|
|
|
|
|
|
|
|
|
| The Potential Influence of Circulating Tumor DNA in Treatment Decisions for Bladder Cancer |
| Petros Grivas, MD, Ph.D. |
| Ashish Kamat hosts Petros Grivas to discuss the potential role of circulating tumor DNA in managing minimal residual disease in bladder cancer. Dr. Grivas highlights that early ctDNA detection could lead to timely treatments, potentially enhancing survival rates. |
|
|
|
|
|
|
|
|
|
|
|
| dMMR and MSI-H in Urothelial Carcinoma: Prevalence and Treatment Implications |
| Elias Chandran, MBBS, FRACP |
| Sam Chang interviews Elias Chandran about a systematic review and meta-analysis on mismatch repair deficiency (dMMR) and microsatellite instability (MSI-H) in urothelial carcinoma. |
|
|
|
|
|
|
|
|
|
|
|
| Determining the Genetic Causes of Bladder Cancer in a Family with Heritable Pattern of Bladder Cancer |
| Aditya Sathe, MD |
| Aditya Sathe presented findings on the genetic causes of bladder cancer in a family with a notable hereditary pattern. This study explored a family with bladder cancer present across three generations, identifying the FANCC pL554P mutation in affected siblings. This research challenges the view that bladder cancer is primarily due to environmental factors, suggesting a significant genetic component. |
|
|
|
|
|
| Urine Tumor DNA-Informed Analysis of ctDNA in Patients with Muscle-Invasive Bladder Cancer - Expert Commentary
|
| Bishoy Faltas, MD
|
| The presence of circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) is indicative of relapse and worsening prognosis. Due to the practical barriers to sequencing tumor samples for ctDNA measurement, medical researchers have focused efforts on developing alternative assays. BinHumaid et al. describe novel approaches to ctDNA detection using blood serum and urine.
|
|
|
|
|
|
|
|
|
|
|
| Added Value of ctDNA Testing For Identifying FGFR3 Alterations In Metastatic Urothelial Cancer Patients Eligible For Erdafitinib Treatment
|
| David C. Müller, MD
|
| David Müller highlights the added value of using circulating tumor DNA testing to identify FGFR3 alterations in metastatic urothelial cancer patients eligible for erdafitinib treatment. While traditional archival tissue testing is the standard for detecting these alterations, ctDNA testing can detect changes in FGFR status that occur during disease progression and post-erdafitinib exposure.
|
|
|
|
|
|
| Prognostic Value of Longitudinal ctDNA in Patients with Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy - Expert Commentary |
| Bishoy Faltas, MD |
| This study by Ben-David et al. examined the prognostic value of longitudinal circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) undergoing radical cystectomy (RC). The study found that detectable ctDNA before surgery was associated with higher pathological stage, increased disease upstaging, and poorer prognosis, including higher rates of recurrence and mortality. |
|
|
|
|
|
| Quantitative Circulating Tumor DNA (ctDNA) Assessment in Patients with Advanced Urothelial Carcinoma Treated with Pembrolizumab or Platinum-Based Chemotherapy from the Phase 3 KEYNOTE-361 Trial |
| Thomas Powles, MBBS, MRCP, MD |
| Thomas Powles presents an ad hoc analysis from the phase 3 KEYNOTE-361 trial, focusing on the prognostic value of quantitative circulating tumor DNA in advanced urothelial carcinoma patients treated with pembrolizumab or chemotherapy. The analysis showed that lower baseline ctDNA levels were linked to improved outcomes with pembrolizumab but not with chemotherapy. |
|
|
|
|
|
| Patient with MIBC After Radical Cystectomy – Can We Use ctDNA to Guide Decisions on Adjuvant Chemo/IO? What About utDNA for Bladder Sparing After NAC? |
| Andrea Necchi, MD, Peter Black, MD, and Jørgen Bjerggaard Jensen, MD, DMSc
|
| At the 2024 EAU annual congress, a debate focused on using ctDNA and utDNA to guide adjuvant therapy in MIBC patients post-radical cystectomy. Professor Peter Black argued that ctDNA/utDNA use is not yet ready due to insufficient evidence, while Professor Jørgen Bjerggaard Jensen highlighted ctDNA's prognostic and predictive value for recurrence and survival, suggesting its potential for personalizing adjuvant therapy, though he acknowledged that utDNA is less established.
|
|
|
|
|
|
| FGFR3 Mutated Urothelial Carcinoma of Bladder or Upper Tract: A Comparative Genomic Landscape Study |
| Michael Basin, MD |
| Michael Basin presents a comparative genomic landscape study of FGFR3 mutated urothelial carcinoma of the bladder and upper tract. The study found that FGFR3 mutations were more common in upper tract UC compared to bladder UC. Additionally, bladder UC patients with FGFR3 mutations had more genomic co-drivers than those with upper tract UC, suggesting potential differences in disease behavior and implications for clinical trial designs targeting FGFR3, including combinations with immunotherapies and antibody-drug conjugates. |
|
|
|
|
|
